Pharmaceutical drug prices and trends for TAMSULOSIN

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
TAMSULOSIN HCL 0.4 MG CAPSULE	00904-7383-61	0.04961	EACH	2026-07-22
TAMSULOSIN HCL 0.4 MG CAPSULE	33342-0159-11	0.04961	EACH	2026-07-22
TAMSULOSIN HCL 0.4 MG CAPSULE	33342-0159-15	0.04961	EACH	2026-07-22
TAMSULOSIN HCL 0.4 MG CAPSULE	33342-0159-44	0.04961	EACH	2026-07-22
TAMSULOSIN HCL 0.4 MG CAPSULE	50268-0740-11	0.04961	EACH	2026-07-22
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Subscribe to access the full database, or Start Trial

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
TAMSULOSIN HCL 0.4MG CAP	Golden State Medical Supply, Inc.	00228-2996-11	100	47.50	0.47500	EACH	2023-06-15 - 2028-06-14	FSS
TAMSULOSIN HCL 0.4MG CAP	Golden State Medical Supply, Inc.	00228-2996-50	500	245.01	0.49002	EACH	2023-06-15 - 2028-06-14	FSS
FLOMAX 0.4MG CAP	Sanofi Aventis U.S. LLC	00024-5837-01	100	648.62	6.48620	EACH	2024-01-01 - 2028-05-31	Big4
FLOMAX 0.4MG CAP	Sanofi Aventis U.S. LLC	00024-5837-01	100	626.70	6.26700	EACH	2023-06-01 - 2028-05-31	Big4
FLOMAX 0.4MG CAP	Sanofi Aventis U.S. LLC	00024-5837-01	100	763.65	7.63650	EACH	2023-06-01 - 2028-05-31	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Unit	>Dates	>Price Type

Last updated: July 10, 2026

Executive summary: Generic tamsulosin dominates global sales across multiple strengths and dosage forms (notably 0.4 mg capsules). Price is already compressed by multi-source generic competition, with the main remaining value drivers shifting to: (1) formulary position and channel contracting (wholesaler and PBM rebates in the US), (2) differentiation between branded originators and specific generic label strengths, and (3) niche demand for controlled-release or specific patient-optimized capsule variants. Near-term US pricing is forecast to remain range-bound with modest declines as supply normalizes, while ex-US markets show more variance due to local tendering, reimbursement rules, and fewer fully interchangeable competitors in some jurisdictions.

What is the global tamsulosin market size and growth outlook?

Fast answer: The global tamsulosin market is largely generic-led and grows at low-to-mid single digit rates driven by demographic aging, benign prostatic hyperplasia (BPH) prevalence, and persistent first-line utilization. Growth is tempered by ongoing generic erosion, tender-driven pricing, and periodic intensity of new entrant manufacturing capacity.

Market segments that move revenues

Tamsulosin revenue is split primarily by:

Dosage form: capsules (most of the volume), tablets in some markets
Strength: commonly 0.4 mg and 0.8 mg (often via combination regimens or separate strengths depending on region)
Release profile: conventional vs modified/controlled-release where local demand exists

Key demand drivers

Aging male population and sustained BPH treatment prevalence
Long treatment duration and low discontinuation relative to episodic therapies
Generic substitution and broad payer coverage

Key competitive forces

Multi-source generic competition in most jurisdictions
Interchangeability and tender price pressure for public-sector procurement
Contracting dynamics (PBMs, pharmacy chains) shaping net price more than list price

How many generic versions of tamsulosin exist and how does that cap pricing power?

Fast answer: In most markets with mature generic frameworks, tamsulosin is widely available in multiple equivalent strengths and capsule configurations, which caps pricing power and compresses unit economics.

What “caps” pricing in practice

Wholesale and pharmacy margin normalization: margin structures constrain shelf pricing adjustments
Tender and reimbursement anchoring: procurement frameworks often reset prices to the low bid or a weighted average
No meaningful differentiation at the molecule level: unless a product has a specific patient adherence advantage, payers treat variants as substitutable

How competition shows up in price behavior

List prices often fall faster in the US than realized net prices decline, due to contracting and rebates
Ex-US: tenders can create step changes where a single supplier displaces another at lower pricing

What is the current US pricing structure for tamsulosin (list vs net)?

Fast answer: US prices for generic tamsulosin are generally low per unit and largely driven by payer contracting, with realized net prices typically below published wholesaler acquisition cost due to rebates and discounts.

Typical pricing dynamics for generics

Initial post-generic entry: rapid downward move as multiple ANDA products launch
Ongoing: modest fluctuations driven by inventory cycles, supply disruptions, and negotiated contract resets
Seasonality: often limited for BPH compared with acute therapies, but ordering patterns can still affect short-term availability and pricing

Why “net price” matters for projections

Forecasts based solely on list price can overstate revenue because:

PBM rebates and wholesaler discounts shift net to payer
Pharmacy reimbursement rules in Medicaid and other programs can anchor dispensing economics

When do tamsulosin prices typically drop further after new generic entries?

Fast answer: Pricing generally declines around two events: (1) the entry of additional ANDA competitors that increase effective supply, and (2) contract resets after tender cycles or pharmacy chain renegotiations.

Timing mechanics

Launch-to-contract lag: revenue impact often shows up over 3 to 9 months as contracts renew
Manufacturing normalization: price can rebound slightly if supply tightens, then resume downtrend when capacity ramps
Wholesaler inventory cycles: temporary pricing variability can occur around allocation events

What price projections apply to tamsulosin through the next 24 months?

Fast answer: A reasonable base case for the US is flat-to-slight decline in realized prices, with most unit price decreases absorbed by volume shifts and contracting rather than large structural changes. Upside is limited unless there is a supply disruption or major competitor exits.

Base case projection (US, annualized)

Year-ahead price trend: modest decline (low single digits)
Two-year price trend: low single digit cumulative decline, with volatility around contract cycles and supply events

Downside and upside scenarios

Downside: additional launches or intensified tender competition push further compression (mid single digits cumulative over two years)
Upside: supply constraints or a reduction in available SKUs stabilizes pricing (near-flat or slight increase in realized net price)

What could change the direction

Major manufacturing disruptions at large suppliers
Regulatory actions that narrow the set of marketable SKUs
Supply normalization causing competition to intensify, not ease

How does tamsulosin pricing differ across Europe, UK, Canada, and Australia?

Fast answer: Europe and other tender-heavy markets often show stronger downward pressure due to reimbursement controls, while Canada and Australia can show sharper supplier-driven swings because of procurement and formulary dynamics.

Europe (high-level pattern)

Tendering and reference pricing drive frequent resets
Discounts to payers are common even when list prices appear stable
Multi-source competition compresses unit price

UK and similar systems

National and regional formulary position plus tariff effects shape net price
Price often aligns with lowest reimbursable offers, with limited room for premiumization

Canada and Australia

Formularies and negotiated supply contracts influence realized pricing
When a supplier loses tender position, price can jump then reset lower when replacement contracts finalize

What are the main formulation and dosage forms that affect market value?

Fast answer: Most volume is in 0.4 mg capsules; 0.8 mg and modified-release variants can matter for gross margin and payer preferences when they reduce dosing frequency or improve adherence.

Dosage forms with commercial relevance

Oral capsules (conventional and modified release)
Oral tablets in some markets
Strength availability shapes interchangeability and tender inclusion

Why form matters even under generics

Dose convenience can shift adherence and patient preference
Some markets apply different reimbursement criteria by strength or presentation
Pharmacist substitution rules can affect switching rates

What patent, exclusivity, and litigation factors still matter for tamsulosin pricing?

Fast answer: Tamsulosin is largely generic in the major markets. Remaining price impact from exclusivity or IP is generally limited to specific formulation, method-of-use, or specific release profile niches, and it does not typically block broad generic competition for the core 0.4 mg capsule.

Practical IP implications

Patent thickets around specific formulations (excipients, release systems) can limit some “design-around” variants
Method-of-use or dosing regimen claims can affect label and promotional positioning, which affects formularies
If a particular generic product has limited FDA marketability, short-term pricing can be supported

What to watch commercially

Loss or gain of specific approved products on the market
Any regulatory actions that remove a high-volume SKU from sale

What is the FDA regulatory status of tamsulosin and how does it affect competitive entry?

Fast answer: Tamsulosin is widely marketed via approved generic pathways; competitive entry is typically driven by ANDA availability and product-specific approvals rather than any ongoing exclusivity for the active ingredient.

Why FDA status affects price

If a SKU is withdrawn or fails quality requirements, the available effective supply shrinks
If a supplier’s ANDA gains market access, competition increases and unit pricing pressures intensify

Market access mechanics

Interchangeability and pharmacy substitution rules affect share shifts
Label strength and release profile affect whether prescribers consider products equivalent

Who are the major manufacturers of generic tamsulosin and how does that shape pricing?

Fast answer: The competitive landscape includes numerous multinational and domestic generic manufacturers. Pricing is sensitive to which firms hold the largest contracted share and which manufacturers maintain consistent supply of the highest-volume SKU strengths.

Commercially relevant factors

Manufacturing scale and consistency drive ability to win tenders
Contract performance influences future supply awards
SKU coverage across strengths reduces friction in switching

How do revenue and price move together for generic tamsulosin?

Fast answer: For generics, revenue is often more sensitive to volume and share than to unit price changes. Even when unit pricing declines, overall revenue can be stable if a product gains contracted share.

Decomposing the drivers

Volume: prescriptions and dispensings, adherence patterns
Net realized price: contract discounts, rebates, wholesaler terms
Mix: strength and formulation share within the total

Mix effects that can offset unit erosion

Higher-volume strength (often 0.4 mg) can be price-competitive but stable
0.8 mg products can carry different payer dynamics and tender inclusion rules

What are the key “generic entry risk” scenarios for tamsulosin?

Fast answer: New entrants rarely create a step change in pricing at the ingredient level now. The more relevant risk is SKU-level entry or exit that changes supply availability during contract resets.

Entry risk scenarios

A new approved product enters a major tender list and undercuts incumbents
A quality event reduces effective supply, creating short-term pricing support for remaining SKUs

Exit risk scenarios

Withdrawal of high-volume SKU breaks contract continuity and can force temporary sourcing substitutions
Manufacturing shutdowns create allocation and can increase realized pricing for the remaining suppliers

Price projections for specific tamsulosin strengths: 0.4 mg vs 0.8 mg

Fast answer: 0.4 mg typically carries the greatest market depth and strongest price compression. 0.8 mg can be slightly more insulated due to different payer coverage patterns and patient selection, but it remains generic-led and exposed to tender competition.

Projection logic

0.4 mg: more competitors, more tender inclusion, faster erosion
0.8 mg: fewer high-volume interchangeable SKUs in some regions, can show slower unit price declines

Key takeaways

Tamsulosin pricing is already largely shaped by multi-source generic competition; the core molecule has limited remaining pricing power in most mature markets.
Near-term US outlook is flat-to-slightly declining realized prices driven by contracting rather than major structural events.
Ex-US markets show more variability due to tendering and reimbursement rules, but the direction remains downward where competition intensifies.
Commercial value is shifting from ingredient-level protection to SKU-level supply stability, formulary positioning, strength mix, and contract wins.

FAQs

1) Why do tamsulosin generic prices vary by pharmacy or wholesaler?
Net realized pricing is shaped by PBM and pharmacy chain contracting, wholesaler discounting, and tender pricing where applicable, which can diverge from published list prices.

2) Does 0.8 mg tamsulosin maintain higher pricing than 0.4 mg?
Often it can be less aggressively compressed in some jurisdictions due to mix and payer coverage patterns, but it remains exposed to the same generic competition mechanics.

3) What supply events most affect tamsulosin pricing?
Manufacturing interruptions, quality-related product suspensions, and sudden allocation events that reduce available marketable SKUs can shift pricing upward temporarily.

4) Can formulary access increase tamsulosin realized price without changing unit list price?
Yes. Contract structure, rebate rates, and preferred formulary placement can improve realized economics even if list prices stay low.

5) What is the biggest driver of future tamsulosin revenue growth if prices decline?
Volume growth from demographic trends plus share gains in contracted accounts (mix shift across strengths and formulations).

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
IQVIA Institute for Human Data Science. Global Medicines Use by Therapy Area (BPH and urology utilization context). IQVIA.
FDA. Drug Shortages. U.S. Food and Drug Administration.
OECD. Pharmaceutical pricing and reimbursement policies (reference pricing, tendering frameworks). Organisation for Economic Co-operation and Development.